Microbial Identification: 16S Gene Sequencing

Comparative DNA sequencing analysis is widely considered to be the best genotypic method for microbial identification. The most common approach is PCR amplification and sequencing of all or a 500bp portion of the 16S ribosomal RNA gene. Sequence data is then compared against a sequence database, which ideally contains only validated microbial sequences.

SeqWright has more than14 years of experience specializing in contract DNA sequencing and bioinformatics, which makes us ideally suited for genotypic microbial identification. Furthermore, our facility is compliant with 21 CFR 58 and 21 CFR 11, and we have implemented all the relevant components of 21 CFR 210/211, including OOS. We guarantee fast turnaround for urgently needed answers and accurate results.

Download the Microbial ID ordering form

IMPORTANT: Investigators and quality assurance officers interested in microbial identification services as a part of an aseptic processing program in response to the FDA's cGMP guidance document issued in September 2004 should visit our cGMP Microbial Identification Testing web page.

Description of Services

Fungal and bacterial identification using genotypic comparative analysis against a VALIDATED microbial sequence library
500bp and full-length 16S ribosomal RNA gene sequencing assays
DNA culturing and isolation
PCR amplification of 16S rDNA
Bi-directional DNA sequencing
Sequence delineation on ABI Prism™ 3730xl DNA sequencers
Analysis and identification using MicroSeq® ID Software
Library of 1400+ validated bacteria entries and 900+ fungal for fast and accurate comparative analysis
3 day turnaround
21 CFR 58 compliant (GLP)
QPCR for microbial detection and quantitation available

Areas of Application

Animal Science
Epidemiology
Biodefense & Microbial Forensics
Marine Science
Biopharmaceutical QC
Medical Microbiology
Bioremediation
Plant Pathology
Clinical Diagnosis
Soil Science and Taxonomy Studies
Dental Research
Entomology

Experience
SeqWright completed sequencing of 5000 full-length gene mutants from a 16S mutant library provided by Ribonovix. The study is a part of a grant awarded to Ribonovix by the NIAID to help develop anti-infectives by identifying new ribosomal drug targets and all viable mutations of these targets, and using these targets for drug screening.